A carregar...
Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis
BACKGROUND: Type 2 diabetes is a risk factor for Alzheimer's disease (AD), most likely linked to an impairment of insulin signalling in the brain. Therefore, drugs that enhance insulin signalling may have therapeutic potential for AD. Liraglutide (Victoza) and exenatide (Byetta) are novel long-...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3352246/ https://ncbi.nlm.nih.gov/pubmed/22443187 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2202-13-33 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|